time
interferon
treatment
patient
sepsi
result
increas
surviv
interleukin
blockad
might
benefit
patient
infect
increas
plasma
concentr
interleukin
isol
shortterm
expans
antivir
direct
cell
proven
lifesav
procedur
patient
autolog
hematopoiet
stemcel
transplant
cytomegaloviru
infect
expans
cell
cellular
drug
could
aid
prepar
tcell
product
adjunct
treatment
patient
sever
infect
sever
uniqu
opportun
evalu
rang
treatment
intervent
peak
sarscov
merscov
outbreak
miss
due
avoid
delay
subsequ
declin
number
case
leav
numer
question
coronaviru
pathogenesi
unansw
disappointingli
treatment
trial
regist
merscov
still
complet
continu
spread
evolv
number
death
rise
exponenti
advanc
new
therapeut
develop
becom
crucial
minimis
number
death
infect
number
confirm
case
novel
coronaviru
report
continu
rise
worldwid
two
blueprint
prioriti
coronavirus
sarscov
merscov
lethal
feb
caus
death
confirm
case
report
specif
antivir
treatment
exist
mainstay
clinic
manag
larg
symptomat
treatment
organ
support
intens
care
serious
ill
patient
unpreced
flurri
activ
global
public
health
bodi
mainli
focus
prevent
transmiss
infect
control
measur
screen
travel
develop
vaccin
receiv
immedi
fund
howev
sarscov
merscov
support
develop
treatment
reduc
mortal
forthcom
urgent
need
focus
fund
scientif
invest
advanc
novel
therapeut
intervent
coronaviru
infect
three
coronavirus
induc
excess
aberr
noneffect
host
immun
respons
associ
sever
lung
patholog
lead
death
similar
patient
sarscov
merscov
patient
develop
acut
respiratori
distress
syndrom
ard
characterist
pulmonari
ground
glass
chang
imag
moribund
patient
infect
also
associ
cytokin
storm
characteris
increas
plasma
concentr
interleukin
granulocytecoloni
stimul
factor
protein
monocyt
chemoattract
protein
macrophag
inflammatori
protein
alpha
tumour
necrosi
factor
surviv
intens
care
aberr
excess
immun
respons
lead
longterm
lung
damag
fibrosi
caus
function
disabl
reduc
qualiti
life
specif
drug
treat
take
sever
year
develop
evalu
meantim
rang
exist
hostdirect
therapi
proven
safe
could
potenti
repurpos
treat
infect
sever
market
drug
excel
safeti
profil
metformin
glitazon
fibrat
sartan
atorvastin
well
nutrient
supplement
biolog
could
reduc
immunopatholog
boost
immun
respons
prevent
curb
ard
zinc
metalcontain
formul
appear
antivir
activ
safe
cheap
readili
avail
formul
could
use
adjunct
monotherapi
combin
therapi
cyclosporin
lopinavirritonavir
interferon
ribavirin
remdesivir
monoclon
antibodi
antivir
peptid
target
tocilizumab
monoclon
antibodi
target
interleukin
receptor
good
safeti
profil
monoclon
polyclon
antibodi
could
develop
postexposur
prophylaxi
ongo
trial
cellular
therapi
treatment
ard
could
expand
treatment
serious
ill
patient
infect
cellular
therapi
use
mesenchym
stromal
cell
allogen
donor
shown
reduc
nonproduct
inflamm
affect
tissu
regener
evalu
phase
trial
patient
ard
infect
appear
initi
associ
increas
respons
might
reflect
physiolog
reaction
curb
overt
inflammatori
respons
clinic
phenomenon
guid
optim
